Enterprise Value
-1.957B
Cash
2.29B
Avg Qtr Burn
-326.2M
Short % of Float
0.96%
Insider Ownership
11.16%
Institutional Own.
34.57%
Qtr Updated
12/31/23
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Eftansomatropin alfa (TJ101) Details Pediatric growth hormone deficiency | BLA Submission | |
Lemzoparlimab combo w/ azacitidine Details High risk myelodysplastic syndromes | Phase 3 Data readout | |
Felzartamab (TJ202) (CD38 mAb) Details Multiple myeloma | Phase 3 Data readout | |
Efineptakin alfa (TJ107) (IL-7) Details Lymphopenia, Solid tumor/s, Cancer, Triple-negative breast cancer , Head and neck squamous cell carcinoma, Glioblastoma | Phase 2 Data readout | |
Uliledlimab (TJD5) (TJ004309) (anti-CD73) +toripalimab Details Cancer, Ovarian cancer | Phase 2 Data readout | |
Uliledlimab (TJD5) (TJ004309) (anti-CD73) Details Cancer, Non-small cell lung carcinoma | Phase 2 Update | |
Felzartamab Details Primary Membranous Nephropathy | Phase 1/2 Update | |
MOR210 (TJ210) Details Solid tumor/s, Cancer | Phase 1 Data readout | |
Givastomig (TJ-CD4B/ABL111) Details Solid tumor/s | Phase 1 Data readout | |
Ragistomig (TJ-L14B/ABL503)(PD-L1 x 4-1BB bispecific antibody) Details Solid tumor/s, Cancer | Phase 1 Update | |
Enoblituzumab (TJ271) + Pembrolizumab Details Head and neck cancer, Cancer, Prostate cancer, Solid tumor/s | Failed Discontinued | |
Olamkicept (TJ301) (gp130 IL-6 inhibitor) Details Ulcerative colitis, Autoimmune disease | Failed Discontinued | |
Felzartamab (MOR202) (CD38) Details IgA nephropathy | Failed Discontinued |